echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The second domestic MASP-2 inhibitor application for clinical application

    The second domestic MASP-2 inhibitor application for clinical application

    • Last Update: 2022-01-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    Author: Shi Bei

    On December 3, the official website of CDE showed that the clinical application of Omeros's monoclonal antibody OMS721 (arsoplimab) injection targeting MASP-2 has been accepted by the State Food and Drug Administration.


    The complement system plays a role in the inflammatory response and is activated due to tissue damage or microbial infection


    Omeros has submitted a BLA application for OMS721 to the FDA for the treatment of thrombotic microangiopathy (HSCT-TMA) after hematopoietic stem cell transplantation.


    In addition, OMS721 has also been developed for the treatment of IgA nephropathy.


    The Phase III ARTEMIS-IGAN ​​trial of OMS721 for the treatment of IgA nephropathy is ongoing


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.